Screening for osteoporosis following non-vertebral fractures in patients aged 50 and older independently of gender or level of trauma energy—a Swiss trauma center approach

Hemmeler, Christoph; Morell, Sabrina; Amsler, Felix; Groß, Thomas

doi:10.1007/s11657-017-0334-3

Cited by 3 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Karlsson and Obrant [45] found, when studying fragility fractures, that 11% were caused by high-energy trauma and 89% by lowenergy trauma. In corroboration with other studies concluding that the cause of trauma preceding the fracture has little or no importance [46,47] we are convinced that the cause of every fracture is not necessary to consider.…”

Section: Discussionsupporting

confidence: 87%

Two methods of evaluating mandibular trabecular pattern in intraoral radiographs and the association to fragility fractures during a 47‐year follow up

Elleby

Skott²,

Jonasson

et al. 2021

European J Oral Sciences

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 87%

Two methods of evaluating mandibular trabecular pattern in intraoral radiographs and the association to fragility fractures during a 47‐year follow up

Elleby

Skott²,

Jonasson

et al. 2021

European J Oral Sciences

View full text Add to dashboard Cite

show abstract

“…With the ongoing aging of society, osteoporosis (OP) has become a common disease, encountered particularly in postmenopausal women, with an incidence of up to 74% [1]. Patients with OP are vulnerable to OP-related fractures, such as critical size bone defects [2,3]. Although tissue-engineered bone substitutes, including various synthetic materials, have been considered, with promising alternatives to bone graft in bone defect repairing [4,5], the treatment of critical size bone defects, particularly under the condition of OP, still has challenging requirements in clinical practice [6,7].…”

Section: Introductionmentioning

confidence: 99%

Modulation of bone formation and resorption using a novel zoledronic acid loaded gelatin nanoparticles integrated porous titanium scaffold: an in vitro and in vivo study

Yang

Wang

et al. 2020

Biomed. Mater.

View full text Add to dashboard Cite

Osteoporotic bone defects are a major challenge in clinics for bone regeneration. With the condition of osteoporosis, excessive bone absorption and impaired osteogenesis result in unexpectedly long healing procedures for defects. In order to simultaneously enhance bone formation and reduce bone resorption, a polydopamine-coated porous titanium scaffold was designed, to be integrated with anti-catabolic drug zoledronic acid nanoparticles (ZOL loaded gelatin NPs), which was able to achieve a local sustained release of ZOL as expected. The in vitro study demonstrated that extracts of the composite scaffolds would stimulate osteoblast differentiation; they also inhibited osteoclastogenesis at a ZOL loading concentration of 50 μmol l−1. In the subsequent in vivo study, the composite scaffolds were implanted into ovariectomy-induced osteoporotic rabbits suffering from femoral condyles defects. The results indicated that the composite scaffolds without ZOL loaded gelatin NPs only induced callus formation, mainly at the interface margin between the implant and bone, whereas the composite scaffolds with ZOL loaded gelatin NPs were capable of further enhancing osteogenesis and bone growth into the scaffolds. Moreover, the research proved that the promoting effect was optimal at a ZOL loading concentration of 50 μmol l−1. In summary, the present research indicated that a new type of porous titanium scaffold integrated with ZOL loaded gelatin NPs inherited a superior biocompatibility and bone regeneration capability. It would be an optimal alternative for the reconstruction of osteoporosis-related defects compared to a traditional porous titanium implant; in other words, the new type of scaffold offers a new effective and practical procedure option for patients suffering from osteoporotic bone defects.

show abstract

Keine Therapie trotz spezifischer Facharzt-Empfehlung?

Groß

2018

Praxis

View full text Add to dashboard Cite

Patient- vs Physician-Reported Implementation of and Compliance to Anti-Osteoporotic Medication One Year after Sustained Fragility Fracture Abstract. We were interested why therapy recommendations made by specialists are often not followed by general practitioners (GPs) and patients. We evaluated systematic questionnaires comparing both, patient and GP statements (n = 151 each) with regard to the implementation of and compliance to specific therapy recommended by an osteologic specialist one year after an osteoporotic fracture. In 53 % GPs prescribed antiosteoporotic drugs, more often if the indication for treatment was less aggressive (p <0.001). Once prescribed, in 94 % of cases the GPs' medication followed the specialists' recommendations. 74 % of patients followed their GP's prescription. Patients most often stated a missing prescription as the reason for not taking drugs (39 %), whereas GPs cited a missing interest of their patients (44 %). The observed discrepancies call for a melioration in the communication between all parties involved.

show abstract

Screening for osteoporosis following non-vertebral fractures in patients aged 50 and older independently of gender or level of trauma energy—a Swiss trauma center approach

Abstract: These preliminary findings appear to confirm the pragmatic approach to screening in a standardized manner for osteoporosis in all non-vertebral fracture patients aged 50 and older-independently of both gender and level of trauma energy.

Cited by 3 publications

References 53 publications

Two methods of evaluating mandibular trabecular pattern in intraoral radiographs and the association to fragility fractures during a 47‐year follow up

Two methods of evaluating mandibular trabecular pattern in intraoral radiographs and the association to fragility fractures during a 47‐year follow up

Modulation of bone formation and resorption using a novel zoledronic acid loaded gelatin nanoparticles integrated porous titanium scaffold: an in vitro and in vivo study

Keine Therapie trotz spezifischer Facharzt-Empfehlung?

Contact Info

Product

Resources

About